The Indian Pharmaceutical Market, Shaped by Government Initiatives, Focuses On Affordable, Top-Tier Medications, Including Generic Drugs, Over-The-Counter Remedies, Vaccines, and More. Despite Potential Obstacles Like Unstable Pricing and Lack of Innovative Drug Development, The Market is Expected To Grow Robustly Due To Increased Demand and Digitalization. Segmentation Includes Therapeutic Category and Pill Type, With Respiratory and Generic Drugs Showing Strong Growth. Key Players Include Cipla Inc., Dr. Reddy's Laboratories Ltd., Lupin, and Sun Pharmaceutical Industries Ltd.

India's pharmaceutical market size was valued at 49 billion U.S. dollars in 2022, with a projection to reach 450 billion dollars by 2047. The market is expected to grow at a CAGR of nine percent in the coming years.

The cardiac market in India grew at about 12 percent from the previous year in financial year 2020, whereas the Indian pharmaceutical market grew at only about ten percent that year. Hypertension drugs formed 65 percent of the cardiac market in the country.

India's domestic pharmaceutical industry's annual turnover reached around 50 billion U.S. dollars in 2023. In 2018, the India pharmaceutical market was valued at 18 billion U.S. dollars. The pharma industry in the country has been doing well despite a fluctuating economy. There was a 9.8 percent year-on-year growth rate recorded in the market in 2019 compared to 2018.

India pharmaceutical market size was worth around USD 55.45 billion in 2023 and is predicted to grow to around USD 156.25 billion by 2032

The Indian Contract Manufacturing Organization (CMO) industry is experiencing robust growth, projected to reach a market size of $22.51 billion in 2025 and maintain a Compound Annual Growth Rate (CAGR) of 14.67% from 2025 to 2033. This expansion is driven by several factors. Firstly, the increasing demand for pharmaceutical products globally, coupled with stringent regulatory requirements and rising R&D costs, incentivizes pharmaceutical companies to outsource manufacturing to specialized CMOs. India's cost-effective manufacturing capabilities, large skilled workforce, and established infrastructure provide a compelling advantage in this landscape. Secondly, the growing focus on generic drugs and biosimilars creates significant opportunities for Indian CMOs, as these products often require large-scale, cost-efficient manufacturing processes. Furthermore, the government's initiatives to promote the pharmaceutical sector, including incentives for investments and streamlined regulatory processes, further bolster the industry's growth. The industry is segmented by service type (API and Intermediates, Finished Dose – Solids, Liquids, Semi-Solids, and Injectables) and caters to a global clientele. Leading players like Cipla, Dr. Reddy's Laboratories, and Sun Pharmaceuticals (though not explicitly listed, a major player assumed to be included in "List Not Exhaustive") are major contributors, signifying the industry's maturity and competitiveness. The market's growth is anticipated to be regionally diverse. While the data doesn't specify exact regional breakdowns, it can be inferred that regions like North America and Europe, with their large pharmaceutical markets and high demand for outsourced manufacturing, will remain significant consumers of Indian CMO services. However, the Asia Pacific region, particularly India itself, is likely to experience disproportionately high growth given the domestic market expansion and the increasing concentration of manufacturing capabilities. Challenges like maintaining quality standards to meet global regulatory norms and managing fluctuating raw material prices remain considerations for sustained growth. Nevertheless, the strong fundamentals and positive outlook suggest the Indian CMO sector is poised for significant expansion in the coming years. Recent developments include: In June of 2022: Glenmark Pharmaceuticals introduced the cutting-edge fixed-dose combination (FDC) medication Indacaterol + Mometasone for patients with uncontrolled asthma in India. The business introduced this FDC under the name Indamet. Glenmark is the first business in India to commercialize the ground-breaking FDC of Indacaterol, a long-acting beta-agonist, and Mometasone Furoate, an inhaled corticosteroid that has been authorized by the Drug Controller General of India (DCGI),, In May 2022: Sun Pharma announced that one of its wholly-owned subsidiaries plans to launch a first-in-class oral drug, Bempedoic Acid, in India for reducing Low-Density Lipoprotein (LDL) cholesterol. The company will launch the drug under the brand name 'Brillo.', In March 2022: The Mumbai-based pharmaceutical business Themis Medicare Ltd. announced that the Drug Controller General of India had approved their antiviral medication VIRALEX (DCGI). In mild to moderate Covid-19 sufferers, the medication aids in the early treatment of clinical symptoms, according to the findings of double-blind, randomized controlled trials (RCT).. Key drivers for this market are: Availability of Skilled Labor at Relatively Lower Cost, Sustained increase in outsourcing volumes by big pharma companies; Geographical advantage in the form of access to large markets in the APAC region. Potential restraints include: The existence of stringent government restrictions and a decrease in the approval of numerous small molecules and biologics in specific regions of the nation. Notable trends are: Generic Medicine Under Solid Finished Dose Segment Holds Significant Share in The Market.

The India pharmaceutical intermediate market is expected to reach USD 2,781.1 million in 2025 and is projected reach a total value of USD 5,587.7 million by 2035. This represents a compound annual growth rate (CAGR) of 7.2% during the forecast period from 2025 to 2035.

Attributes	Values
Estimated India Industry Size (2025)	USD 2,781.1 million
Projected Global Value (2035)	USD 5,587.7 million
Value-based CAGR (2025 to 2035)	7.2%

The pharmaceutical eCommerce market value is estimated to be US$ 75,527.4 million in 2024. The market is predicted to grow at a CAGR of 14.4% during the forecast period. The market valuation is estimated to reach US$ 290,824.8 million by 2034.

Report Attribute	Details
Pharmaceutical eCommerce Market Size (2024)	US$ 75,527.4 million
Anticipated Market Value (2034)	US$ 290,824.8 million
Projected Growth Rate (2024 to 2034)	14.4% CAGR

Historical Analysis of the Pharmaceutical eCommerce Market Vs Demand Outlook

Attributes	Details
Pharmaceutical eCommerce Market Value (2019)	US$ 54,772.1 million
Historical Market Revenue (2023)	US$ 73,315.6 million
Historical CAGR (2019 to 2023)	7.6%

Country-wise Insights

Countries	CAGR (2024 to 2034)
United States	7%
Germany	8%
United Kingdom	8.7%
India	20.7%
China	16%

Category-wise Insights

Attributes	Details
Top Product Type	Over-the-counter Product
Market Share in 2024	63.7%

Attributes	Details
Top End User	Consumer or Individuals
Market Share in 2024	29.8%

Pharmaceutical eCommerce Market Report Scope

Attribute	Details
Estimated Market Size (2024)	US$ 75,527.4 million
Projected Market Size (2034)	US$ 290,824.8 million
Anticipated Growth Rate (2024 to 2034)	14.4%
Forecast Period	2024 to 2034
Historical Data Available for	2019 to 2023
Market Analysis	US$ million or billion for Value and Units for Volume
Key Regions Covered	North America, Latin America, Europe, Middle East & Africa (MEA), East Asia, South Asia and Oceania
Key Segments Covered	By Product Type, By End Use Verticals, and By Region
Key Companies Profiled	Netmeds Marketplace Ltd. EasyMedico Medlife Amazon. Inc Apotek The Kroger Co. Walgreen Co. Giant Eagle, Inc. Walmart Express Scripts CVS Health Optum, Inc. L Rowland & Co (Retail) Ltd Zur Rose Group AG McKesson Corporation SHOP-APOTHEKE EUROPE N.V. UK Meds Direct Ltd. Walgreens Boots Alliance, Inc. DocMorris
Report Coverage	Market Forecast, Company Share Analysis, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives
Customization & Pricing	Available upon Request

The India Pharmaceutical Packaging Market Report is Segmented by Material Type (Plastic, Glass, and Other Material Types) and Product Type (Bottles, Vials and Ampoules, Syringes, Tubes, Caps and Closures, Pouches and Bags, Labels, and Other Product Types). The Market Sizes and Forecasts are Provided in Terms of Value (USD) for all the Above Segments.

Snapshot img

India Active Pharmaceutical Ingredient Market Size 2025-2029

The India active pharmaceutical ingredient (API) market size is forecast to increase by USD 11.18 billion billion at a CAGR of 7.4% between 2024 and 2029.

The Active Pharmaceutical Ingredient (API) market is experiencing significant growth, driven by several key factors. One major trend is the increasing number of Type II Drug Master Files (DMFs), which facilitate the global exchange of information between regulatory authorities and manufacturers, streamlining the regulatory approval process. This market exhibits strong growth, driven by the increasing prevalence of chronic diseases such as cardiovascular diseases, cancer, and chronic disorders. Another significant development is the paradigm shift in API manufacturing, with a move towards more advanced technologies such as continuous manufacturing and solid-state chemistry. The stringent regulatory environment also continues to shape the market, with regulatory bodies imposing stricter quality standards and increasing scrutiny on API manufacturing processes. These factors, among others, are expected to drive market growth and shape the future of the API industry.

What will be the Size of the market During the Forecast Period?

Request Free Sample

The market encompasses the production and supply of essential elements used in manufacturing pharmaceutical drugs. The demand for APIs is further fueled by the expansion of the generic drugs sector, which accounts for a significant portion of the market share. In the healthcare landscape, APIs play a pivotal role in addressing critical health concerns, including infectious diseases and hospital-acquired infections. The market is witnessing a shift towards plant-based APIs and synthetic counterparts, as they offer advantages in terms of efficacy, safety, and cost-effectiveness.


Moreover, product development strategies, including collaborations, mergers and acquisitions, and research and development initiatives, are shaping the competitive dynamics of the API market. The cardiology and oncology segments are among the fastest-growing sectors, reflecting the high unmet medical needs and the increasing focus on developing targeted therapies. The global API market is anticipated to continue its upward trajectory, underpinned by ongoing research and development efforts and the growing demand for effective and affordable medicines.

How is this market segmented and which is the largest segment?

The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

Manufacturing Type

  Captive APIs
  Contract APIs


Type

  Innovative APIs
  Generic APIs


Product Type

  Prescription
  Over-the-counter (OTC)


Application

  Cardiovascular diseases (CVDs)
  Oncology
  Infectious diseases
  Diabetes
  Others


Geography

  India

By Manufacturing Type Insights

The captive APIs segment is estimated to witness significant growth during the forecast period. The market has witnessed substantial growth due to the increasing focus on affordable healthcare services and the rising demand for low-cost medicines. Captive APIs, which are developed in-house by pharmaceutical companies for their medication production, accounted for the largest market share in 2024. The adoption of Contract Manufacturing Organizations (CMOs) for outsourcing the production of bulk actives or late-stage intermediates is a significant trend in the industry. This shift towards outsourcing is driven by the need to reduce manufacturing costs and improve efficiency. Infectious diseases, hospital-acquired infections, chronic diseases, cardiovascular diseases, and chronic disorders continue to be major therapeutic areas for API development.

Get a glance at the market report of share of various segments Request Free Sample

Market Dynamics

Our India Active Pharmaceutical Ingredient (API) Market researchers analyzed the data with 2024 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

What are the key market drivers leading to the rise in adoption of India Active Pharmaceutical Ingredient (API) Market?

Increasing number of type II drug master files (DMF) is the key driver of the market. The market experiences significant growth due to the increasing prevalence of chronic diseases such as cardiovascular diseases and chronic disorders. The market is driven by the demand for prescription drugs to treat these conditions, with synthetic APIs, including Proton Pump Inhibitors, playing a crucial role. The Over-the-counter (OTC) segment also contributes to the market's expansion, with health supplements being

Snapshot img

Pharmaceutical Equipment Market Size 2025-2029

The pharmaceutical equipment market size is forecast to increase by USD 6.38 billion at a CAGR of 6.9% between 2024 and 2029.

The market is witnessing significant growth due to several key trends. The rising prevalence of diseases and the subsequent increase in demand for pharmaceuticals are major growth factors. Standardization across pharmaceutical equipment is another trend driving market growth. However, the high cost of pharmaceutical equipment remains a challenge for market expansion. Despite this, advancements in technology and automation are expected to provide opportunities for market growth. Automation, robotics, artificial intelligence, and machine learning are becoming increasingly important in the market. Overall, the market is anticipated to experience steady growth in the coming years.

What will be the Size of the Market During the Forecast Period?

Request Free Sample

The pharmaceutical industry is experiencing significant growth due to the aging population and the rising prevalence of chronic health conditions, including chronic diseases such as cancer, diabetes, and cardiovascular disease. This trend is driving the demand for advanced pharmaceutical equipment to meet the increasing production requirements and ensure the production of personalized medicines based on genetic information. These technologies enable the industry to improve efficiency, reduce costs, and ensure regulatory compliance. The use of automation and robotics in the production process allows for the streamlining of supply chain operations, optimizing inventory levels, and maintaining production schedules.
In addition, roll forming machines, uncoilers, coil cars, flatteners, roll form dies, roll formers, and presses are essential equipment in the pharmaceutical industry. These machines enable the production of high-quality pharmaceutical components, ensuring the production of effective and safe medicines. Customer service plays a crucial role in the market. Providers of pharmaceutical equipment must ensure that their equipment meets the highest standards of quality and reliability. Bob Repovs, a leading equipment sales representative, prioritizes the importance of providing excellent customer service to meet the unique needs of each client. Regulations and compliance requirements are a significant factor in the market.

How is this market segmented and which is the largest segment?

The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

Product Type

  Solid
  Liquid


Type

  Packaging equipment
  Granulating equipment
  Spray drying equipment
  Filing machines
  Others


End-User

  Pharmaceutical manufacturing companies
  Contract manufacturing organizations


Geography

  North America

    Canada
    US


  Europe

    Germany
    UK
    France
    Italy


  Asia

    China
    India
    Japan


  Rest of World (ROW)

By Product Type Insights

The solid segment is estimated to witness significant growth during the forecast period.The market encompasses the production of equipment used in the manufacturing of Oral Solid Dosage (OSD) forms of pharmaceuticals. OSD forms, including tablets, capsules, and powders, offer advantages such as ease of administration, stability, accurate dosing, and controlled release. Notable companies in this sector include Syngenton, GEA Group, Romaco, and Korber. OSD forms are preferred due to their user-friendly nature, as they are simple to handle and require minimal preparation time. This attribute enables patients to self-administer medication at home, enhancing convenience and autonomy. The integration of technologies such as automation, robotics, artificial intelligence, and machine learning further streamlines the manufacturing process, ensuring efficiency and precision.

Get a glance at the market report of share of various segments Request Free Sample

The solid segment was valued at USD 7.50 billion in 2019 and showed a gradual increase during the forecast period.

Regional Analysis

Asia is estimated to contribute 37% to the growth of the global market during the forecast period.Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

For more insights on the market share of various regions Request Free Sample

Another region contributing to the market growth is North America. The North American market is primarily driven by the presence of a significant number of large-scale pharmaceutical and biotechnology companies based in the United States. One notable example is Pfizer Inc., a leading global pharmaceutical company headquartered in New York, which utilizes a wide range of phar

India White Oil Market size is valued at USD 110.91 Million in 2023 and is anticipated to reach USD 161.52 Million by 2031, growing at a CAGR of 4.8% from 2024 to 2031.

Key Market Drivers:
Growing Demand in Cosmetics: The cosmetics and personal care industry is expanding rapidly, with an expected market growth rate of 8-10% annually. White oil is widely used in products like moisturizers and makeup removers, driving its demand in this sector.

Expanding Pharmaceutical Industry: The Indian pharmaceutical sector is projected to grow significantly, with an expected market size of USD 130 Billion by 2030. White oil’s applications in creams, ointments, and laxatives make it essential for pharmaceutical manufacturing.

Increased Production Capacities: Major pharmaceutical companies are continuously increasing their production capabilities, which is anticipated to boost the demand for white oil as a key ingredient in various formulations.
Versatility Across Industries: White oil’s versatility allows its use in multiple applications beyond cosmetics and pharmaceuticals, including food processing and plastics. This broad applicability supports sustained demand across various sectors.

The cardiac market volume in India grew at about four percent from the previous year in financial year 2020, whereas the Indian pharmaceutical market grew at only about two percent that year. Hypertension drugs formed 65 percent of the cardiac market in the country during the same time period.

The size of the Indian Pharmaceutical Industry market was valued at USD XX Million in 2023 and is projected to reach USD XXX Million by 2032, with an expected CAGR of 10.70% during the forecast period. In fact, Indian pharmaceuticals is a vibrant, dynamic, and fast-growing sector, regarded as one of the biggest pharmaceutical industries in the world. Apart from general drugs, APIs, and biosimilars, India provides generic forms of an enormous range of pharmaceutical products. Growth of India's pharmaceutical industry can be attributed to other factors like more expenditure on healthcare, increased presence of chronic diseases, and large population needing cheap medicines. Further strong manufacturing capabilities, a skilled workforce, and a favorable regulatory environment have catapulted India into a global hub for the manufacturing of pharmaceuticals. The country provides around 20% of the generic medicines supplied in the world, with pharmaceutical exports increasing substantially over the past several years, particularly towards developed markets such as the United States and Europe. Some emerging trends include innovation in drug development, where research and the development of new drugs are given emphasis to ensure that those drugs will indeed be novel in their treatment. Biotechnology and digital health solutions also determine changes happening in this field, developing tailored medicines and treatments highly advanced. Despite the demand headwinds of high regulatory standards and strong competition from other low-cost manufacturing countries, the Indian pharmaceutical industry will experience headwinds including high regulatory standards and strong competition from other low-cost manufacturing countries. However, given the right actions by the government to enhance production and innovation and to provide access to the much-needed medicines, this Indian pharmaceutical industry would be exceptionally well-positioned for future growth and be a critical player in the future global health arena. Recent developments include: In February 2022, Dr. Reddy's Laboratories Ltd. announced that the Drugs Controller General of India (DCGI) had approved the single-shot Sputnik Light vaccine for restricted use in an emergency in India., In November 2021, Cipla Limited was granted EUA permission by the DCGI for the launch of Molnupiravir in India, the first oral antiviral approved by the United Kingdom Medicines and Healthcare Products Regulatory Agency (MHRA) for the treatment of mild-to-moderate COVID-19 at high risk of developing severe disease.. Key drivers for this market are: Low Cost of Production and Increased R&D Activities, Increased Expenditure on Healthcare and Medicine. Potential restraints include: Lack of a Stable Pricing and Policy Environment, Lack in Development of Innovative Drugs. Notable trends are: The Respiratory Therapeutic Category Segment is Expected to Show Healthy Market Growth in the Forecast Period.

The India pharmaceutical market is valued at USD 65 billion, based on a comprehensive historical analysis. It is driven by a range of factors, including a rising population and an increasing incidence of chronic diseases such as diabetes and cardiovascular ailments. A growing emphasis on generic drugs also plays a pivotal role, along with government initiatives.

According to Cognitive Market Research, the global active pharmaceutical ingredient market size will be USD 165245.2 million in 2024. It will expand at a compound annual growth rate (CAGR) of 7.2% from 2024 to 2031.

North America held the major market share for more than 40% of the global revenue with a market size of USD 66098.08 million in 2024 and will grow at a compound annual growth rate (CAGR) of 5.4% from 2024 to 2031.
Europe accounted for a market share of over 30% of the global revenue with a market size of USD 49573.56 million.
Asia Pacific held a market share of around 23% of the global revenue with a market size of USD 38006.40 million in 2024 and will grow at a compound annual growth rate (CAGR) of 9.2% from 2024 to 2031.
Latin America had a market share of more than 5% of the global revenue with a market size of USD 8262.26 million in 2024 and will grow at a compound annual growth rate (CAGR) of 6.6% from 2024 to 2031.
Middle East and Africa had a market share of around 2% of the global revenue and was estimated at a market size of USD 3304.90 million in 2024 and will grow at a compound annual growth rate (CAGR) of 6.9% from 2024 to 2031.
The synthetic APIs category is the fastest growing segment of the active pharmaceutical ingredient industry

Market Dynamics of Active Pharmaceutical Ingredient Market

Key Drivers for Active Pharmaceutical Ingredient Market

Production Capacity Expansion in Pharmaceutical and Biopharmaceutical Companies to Boost Market Growth

Pharmaceutical and biopharmaceutical companies are expanding production capacities to meet the growing demand for active pharmaceutical ingredients (APIs). This expansion is driven by the increasing prevalence of chronic diseases, aging populations, and rising demand for innovative therapies. Companies are investing in new facilities, advanced manufacturing technologies, and scaling up existing operations to enhance API production. This growth supports drug development and ensures a stable supply chain, especially for high-demand medications. Additionally, regulatory support and partnerships are boosting the production of APIs, further driving the pharmaceutical market's expansion. For instance, in November 2023, Novo Nordisk announced plans to expand its existing manufacturing capacity by building a new API facility in Kalundborg, Denmark. An investment of more than USD 6 billion was made in the project to enhance capacity throughout the entire global value chain, from API production to packaging.

Favorable Regulations for R&D Facilities to Drive Market Growth

Favorable regulations for R&D facilities are boosting growth in the active pharmaceutical ingredient (API) market. Governments worldwide are implementing policies that support innovation in pharmaceutical research, including tax incentives, streamlined approval processes, and funding for R&D activities. These regulations encourage pharmaceutical companies to invest in developing new and improved APIs, which are essential for drug formulation. The supportive environment accelerates innovation, reduces costs, and enhances the competitiveness of API manufacturers, driving market expansion. It also fosters collaboration between academia, industry, and regulatory bodies, further advancing pharmaceutical development.

Restraint Factor for the Active Pharmaceutical Ingredient Market

Limited Availability of Raw Material Will Limit Market Growth

The limited availability of raw materials is a key challenge in the active pharmaceutical ingredient (API) market. API production relies heavily on specific raw materials, which are subject to supply chain disruptions, geopolitical issues, and environmental regulations. These constraints can lead to delays in drug manufacturing and higher production costs. Additionally, reliance on a few global suppliers, especially from countries like China and India, exacerbates the risk of shortages. As a result, pharmaceutical companies are increasingly seeking alternative sources and more sustainable raw material supply chains to mitigate these risks.

Impact of Covid-19 on the Active Pharmaceutical Ingredient Market

The COVID-19 pandemic significantly impacted the active pharmaceutical ingredient (API) market, disrupting global supply chains and highlighting dependency on specific regions, particularly China and India, for API production. Demand for APIs surged due to the increased need for medicat...

According to Cognitive Market Research, the global Medicine market will be USD XX million in 2024 and will expand at a compound annual growth rate (CAGR) of 5.10% from 2024 to 2031.

North America held the major market share, more than 40% of the global revenue, with a market size of USD XX million in 2024. It will grow at a compound annual growth rate (CAGR) of 3.3% from 2024 to 2031.
Europe accounted for over 30% of the global USD XX million market size.
Asia Pacific held a market share of around 23% of global revenue, with a market size of USD XX million in 2024, and will grow at a compound annual growth rate (CAGR) of 7.1% from 2024 to 2031.
Latin America's Market will have more than 5% of the global revenue with a market size of USD 1XX million in 2024 and will grow at a compound annual growth rate (CAGR) of 4.5% from 2024 to 2031.
The Middle East and Africa held the major market share, around 2% of the global revenue, with a market size of USD XX million in 2024. The market will grow at a compound annual growth rate (CAGR) of 4.8% from 2024 to 2031.
The hospital held the highest Medicine market revenue share in 2024.

Market Dynamics of Medicine Market

Key Drivers of Medicine Market

Growing Patient Awareness and Demand to Provide Viable Market Output

The growing patient awareness and demand significantly increase global demand. As patients become more informed about healthcare options, treatments, and preventive measures, they actively seek out solutions to address their health concerns. This increased awareness leads to a higher demand for pharmaceuticals, medical devices, and healthcare services. Patients are more inclined to participate in their own healthcare decisions, driving demand for innovative treatments and therapies. Additionally, advancements in technology and access to information empower patients to explore alternative medicine options, contributing to the expansion of the medicine market. Overall, the trend towards greater patient awareness and demand fuels growth and innovation within the healthcare industry.

For instance, in March 2021, in India, Hyderabad-based health supplements startup Fitday announced plans to launch 50 brick-and-mortar stores by 2023 across India with an investment of USD 8 million. This omnichannel startup has a product portfolio that includes vitamins, minerals, immunity boosters, sports nutrition products, and Ayurvedic herbs.

(Source: https://www.businesstoday.in/latest/corporate/story/health-supplements-startup-fitday-stores-india-hyderabad-website-covid-19-pandemic-isopure-nestle-and-optimum-nutrition-293276-2021-04-12)

New Launches to Propel Market Growth

The new launches aim to provide growth in the Market. Pharmaceutical companies invest heavily in research to introduce novel drugs that address unmet medical needs or offer improved efficacy, safety, or convenience compared to existing treatments. These new launches often target prevalent diseases such as cancer, cardiovascular conditions, or infectious diseases, driving market growth by expanding treatment options and improving patient outcomes. Additionally, regulatory approvals, advancements in biotechnology, and increasing healthcare expenditure globally further stimulate the introduction of new medicines. Consequently, the medicine market thrives on a cycle of innovation, with ongoing launches contributing to its dynamism and growth.

For instance, in November 2020 - Kunnath Pharmaceuticals, a manufacturer of herbal products, launched antiviral immunity booster capsules across India under the brand name 'Viromune.' Through this launch, the firm was looking to achieve a turnover of USD 266 million over the next three years.

(Source: https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/kunnath-pharmaceuticals-launches-antiviral-herbal-product-across-india/articleshow/79060893.cms?from=mdr)

Restraint Factors of Medicine Market

High Development Costs to Restrict Market Growth

The Medicine market faces challenges due to the high development costs. Pharmaceutical research and development demand extensive financial investments, encompassing preclinical studies, clinical trials, and regulatory compliance. These costs often soar due to stringent safety and efficacy standards, prolonged testing phases, and complex manufacturing processes. Additionally, the need for constant adaptation to evolving...

Pharmaceutical intermediates market is growing with a CAGR of 4.5% across the forecast period with revenue expanding from USD 36,620.2 million in 2025 to USD 57,031.9 million by 2035. The market currently sits at USD 35,081.4 million in 2024.

Attributes	Key Insights
Industry Size (2025E)	USD 36,620.2 million
Industry Value (2035F)	USD 57,031.9 million
CAGR (2025 to 2035)	4.5%

Semi Annual Market Update

Particular	Value CAGR
H1	5.5% (2024 to 2034)
H2	5.1% (2024 to 2034)
H1	4.5% (2025 to 2035)
H2	4.2% (2025 to 2035)

Country-wise Insights

Countries	Value CAGR (2025 to 2035)
UK	3.0%
China	6.4%
India	7.2%
Germany	3.3%
USA	3.2%
Saudi Arabia	2.3%

Category-wise Insights

Product	Value Share (2024)
Bulk Drug Intermediates	65.5%

End User	Value Share (2024)
CMOs/ CROs	66.8%

Generic drugs have been a stronghold of the Indian pharmaceutical industry and as of 2020, it contributed to 70 percent of the total market revenue. At the same time, patented drugs amounted to just nine percent of the market revenue pointing to a need for further research and development in the country in order to increase the patent drug applications.

Generics and the market size

Generic drugs are copies of the original chemical substances that make up branded drugs. Once the patents on the original drugs expire, other pharma companies can sell these drug copies at a much cheaper price. Generic prescription drugs generated a revenue of around 79 billion U.S. dollars worldwide in fiscal year 2019 and this was expected to go up to 100 billion dollars by 2024. At the same time, it was estimated that India would generate around 28 billion dollars’ worth of revenue from generics in the prescribed drug market by 2020.

The case for Indian generics and affordability

Apart from the revenue potential from generics, it is also a cornerstone in making cheap medicines available to the masses. In 2019, India’s pharmaceutical exports were largely focused on places with high out-of-pocket health expenditures like the United States and Africa. As healthcare expenditure keeps rising world-over, the importance of affordable medicines through quality assured generics will be the need of the hour.

The global pharmaceutical market is expected to grow at a CAGR of 5% during 2011-2017, exceeding sales worth US$ 1.1 Trillion by 2017. This market, however, is expected to undergo a number of transitions which would impact the course of its growth. These transitions include a shift of growth from the developed to the emerging markets, an increasing focus on biopharmaceuticals compared to small molecule drugs and an increasing preference for generics compared to their branded versions. As a result of these transformations; the need for a user friendly, robust and comprehensive pharmaceutical market intelligence has become imperative for investors, researchers, consultants, marketing strategists, and all those who are planning to foray into the pharmaceutical market in some form or the other.

IMARC Group, one of the world’s leading research and advisory firms, introduces a new and revolutionary way to understand and evaluate the global pharmaceutical market with its Microsoft Excel based report entitled “Global Pharmaceutical Market Report & Forecast: 2012-2017”. This report provides an analytical and statistical insight into the global pharmaceutical market. The study, which has been undertaken using desk based as well as primary market research has analyzed the following aspects of the global pharmaceutical market.

What We Have Achieved in This Report?

Regions Covered: Global, North America, Europe, Asia Pacific, Latin America & Caribbean and Middle East & Africa

Countries Covered in Each Region

North America: United States and Canada

Europe: Germany, France, Italy, Spain, United Kingdom, Russia, Turkey, Netherlands, Poland, Greece, Belgium, Switzerland, Austria, Sweden, Portugal, Hungary, Romania, Denmark, Czech Republic, Finland, Ireland, Norway, Slovakia, Bulgaria, Croatia, Slovenia, Lithuania, Latvia, Luxembourg and Estonia

Asia Pacific: Japan, China, South Korea, Australia, India, Taiwan, Indonesia, Thailand, Philippines, Pakistan, Vietnam, Bangladesh, Hong Kong, New Zealand, Malaysia and Singapore

Latin America & Caribbean:Brazil, Mexico, Venezuela, Argentina, Puerto Rico, Colombia, Chile, Ecuador, Peru, Dominican Republic and Uruguay

Middle East & Africa: South Africa, Egypt, Saudi Arab, Algeria, Morocco, United Arab Emirates Lebanon, Tunisia, Jordan and Kuwait

Focus of the Analysis:

• Historical sales performance (2007-2011) for each country
• Historical sales performance (2007-2011) for each region
• Sales forecast (2012-2017) for each country
• Sales forecast (2012-2017) for each region
• Sales performance of key manufacturers for each country (2007-2011)
• Sales performance of key therapeutic areas for each country (2007-2011)
• Country wise sales breakup for each region (2007-2011)
• Country wise sales breakup forecast for each region (2012-2017)

Key Questions Answered;

• What was the historical performance of the global pharmaceutical market?
• Which are the key regions and countries in the global pharmaceutical market?
• Which are the largest pharmaceutical markets in the world?
• Which are the fastest growing pharmaceutical markets in the world?
• Which markets are expected to witness the slowest growth in the coming years?
• Which countries represent the key markets for each region?
• What has been the performance of various therapeutic classes in each country?
• Who are the top pharmaceutical manufacturers in each country?
• What are the market shares of the top pharmaceutical manufacturers in each country?

Why You should Buy This Report?

• To gain a comprehensive understanding on the historical, current and future pharmaceutical market trends across 70 countries in 6 regions.
• To identify potential regions, countries, therapeutic areas, partners and competitors for market entry and expansion plans.
• As a tool for developing investment strategies by identifying the biggest winners and losers across various regions and countries.
• To ensure a successful M&A and partnership strategy by identifying therapeutic areas and companies with the most promising outlook.